Allergy Diagnostics Market Growth Outlook (2025-2032): Rising Allergy Burden and Diagnostic Innovation Drive Market Expansion by DelveInsight

The Allergy Diagnostics Market By Type (Products [Instruments and Consumables], and Services), By Allergy Type (Food Allergy, Drug Allergy, Inhalant Allergy, and Others), By Diagnostic Test Type (In-Vivo and In-Vitro), By End User (Hospitals, Diagnostic Centers, and Others), and By Geography, is expected to grow at a significant CAGR through 2032, propelled by the increasing incidence of allergies such as food and drug hypersensitivity disorders, coupled with continuous innovation in diagnostic technologies.

The Global Allergy Diagnostics Market was valued at USD 4.58 billion in 2024, and is projected to reach USD 8.93 billion by 2032, expanding at a CAGR of 11.78% between 2025 and 2032. The market's rapid progression is largely attributable to the escalating prevalence of allergic diseases, supportive regulatory approvals, and the emergence of high-throughput and precision-based diagnostic systems.

Download the Full Allergy Diagnostics Market Report Now! Stay Ahead of Emerging Trends! @ https://www.delveinsight.com/report-store/allergy-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Allergy Diagnostics Market Dynamics
Key Allergy Diagnostics Market Growth Drivers
One of the most influential factors contributing to market expansion is the rising global burden of allergic diseases. According to the World Health Organization (2023), asthma affected 262 million people globally in 2019. In India, asthma impacts 2% of adults and 6% of children, as reported by the Global Asthma Report (2018).
Similarly, drug allergies are becoming increasingly common, with WHO stating that adverse drug reactions account for 3-6% of hospital admissions globally, and 10-15% of cases occurring in hospitalized patients. In outpatient settings, up to 25% of prescriptions may be associated with allergic responses.
Data from the American Academy of Asthma, Allergy & Immunology (2023) suggests that Allergic Rhinitis affects 10-30% of the global population, highlighting a strong unmet need for standardized and accessible diagnostic protocols. Allergies can manifest from mild discomfort to life-threatening anaphylaxis, making early detection via skin prick tests (SPT), specific IgE testing, and molecular assays crucial for clinical management.
Furthermore, deteriorating air quality due to rapid urbanization and industrial emissions is exacerbating allergy rates. A WHO 2021 report indicated that 99% of the global population lived in environments exceeding WHO pollution limits. Particulate matter (PM2.5), cigarette smoke, pollen load, and vehicular emissions are major triggers for respiratory allergy flare-ups, thereby increasing demand for diagnostic evaluation.

Allergy Diagnostics Market Restraints
Despite the strong growth trajectory, certain challenges impede market adoption:
• High costs associated with allergy diagnostic instruments, particularly automated analyzers and multiplex immunoassay platforms.
• Limited awareness in low-income regions, where allergies are often misdiagnosed or untreated.
• Short-term disruption during the COVID-19 pandemic, where healthcare resources were reallocated toward infection control, temporarily affecting the adoption of allergy diagnostics.
However, the post-pandemic reopening of diagnostic centers and hospitals, coupled with resumption of allergy screening programs, has restored growth momentum.

Request Your Free Sample PDF to Unlock Key Market Insights and Strategic Opportunities @ https://www.delveinsight.com/sample-request/allergy-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Allergy Diagnostics Market Segment Analysis
Allergy Diagnostics By Allergy Type
Among allergy categories, the drug allergy segment is projected to hold a significant market share through 2032. This dominance is supported by a rising prevalence of medication-induced hypersensitivity reactions, particularly from antibiotics, NSAIDs, and chemotherapeutics. The American Academy of Asthma, Allergy & Immunology (2021) revealed that drug allergies account for up to 20% of global anaphylaxis-related fatalities. As personalized medicine advances, allergy testing is expected to become mandatory prior to prescribing high-risk medications, further strengthening this segment.

Allergy Diagnostics By Diagnostic Type
The market is divided into In-Vivo and In-Vitro diagnostics:
• In-Vivo Tests include Skin Prick Testing (SPT) and Intradermal Tests, widely utilized in clinical and outpatient allergy centers due to speed and low cost.
• In-Vitro Tests-notably ImmunoCAP assays, ELISA-based IgE testing, and component-resolved diagnostics (CRD)-are gaining traction due to higher accuracy and safety, particularly in high-risk or pediatric patients.
The In-Vitro segment is expected to demonstrate higher growth potential, driven by automation and integration with digital reporting systems.

Allergy Diagnostics By Type: Products vs. Services
• Consumables (allergen reagents, assay kits) account for recurring revenue streams, making them the largest revenue generator in the segment.
• Diagnostic services are witnessing increased outsourcing by hospitals and clinics, offering cost-efficient processing through central reference laboratories.

Allergy Diagnostics By End User
• Hospitals remain the leading end users due to their full-scale allergy workup capabilities, including immediate reaction monitoring.
• Diagnostic Centers are expected to register the highest CAGR, propelled by expanded insurance coverage and direct-to-consumer testing models.

Book a Consultation with Our Healthcare Market Analysts for Customized Growth Projections @ https://www.delveinsight.com/sample-request/allergy-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Allergy Diagnostics Regional Insights
North America Leads the Global Market
North America is projected to dominate the allergy diagnostics market through 2032, driven by:
• High awareness and adoption of allergy screening protocols
• Favorable reimbursement infrastructure
• Strong presence of key manufacturers and clinical laboratories

In the United States, allergy prevalence is notably high. According to the Asthma and Allergy Network (2020):
• 6.5% of children under 18 suffer from food allergies
• 9.6% of the total population is affected by respiratory allergies
• 19.2 million Americans were diagnosed with hay fever in 2020, per the CDC

Additionally, regulatory-backed product launches and collaborations have accelerated market penetration. For example:
• In December 2018, Hycor Biomedical Inc. secured FDA approval for its NOVEOS automated allergy testing platform.
• In July 2020, Thermo Fisher Scientific received FDA clearance for the ImmunoCAP Specific IgE α-Gal component test.
Europe is expected to remain the second-largest market, followed by Asia-Pacific, which is anticipated to deliver accelerated growth due to rising diagnostic infrastructure and pollution-driven allergy prevalence.

Access Exclusive Vendor Profiles and Competitive Benchmarking! Get Started Today @ https://www.delveinsight.com/sample-request/allergy-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Allergy Diagnostics Competitive Landscape
Key Allergy Diagnostics Companies include:
• HOB Biotech Group Corp., Ltd.
• Thermo Fisher Scientific
• Siemens Healthineers
• Danaher Corporation
• Romer Labs Division Holding
• EUROIMMUN Medizinische Labordiagnostika AG
• HollisterStier Allergy
• Eurofins Scientific
• Omega Diagnostics Group plc
• HYCOR Biomedical
• R-Biopharm AG
• AEKSU GROUP GmbH
• ACON Laboratories, Inc.
• Lincoln Diagnostics, Inc.
• Astra Biotech GmbH
• Erba Group
• Hitachi Chemical Diagnostics Inc.
• Hemostasis Inc.
• BioMérieux SA
• PerkinElmer Holdings Ltd.

Notable Strategic Developments in Allergy Diagnostics Market
• July 2021: PerkinElmer acquired IDS, expanding its allergy testing product line.
• April 2019: Bluejay Diagnostics received CE approval for ALLEREYE Tear Total IgE Test, a non-invasive POC solution for allergic conjunctivitis.

Allergy Diagnostics Future Outlook and Opportunities
The Allergy Diagnostics Market presents lucrative prospects, particularly in:
• Molecular allergy testing - enabling component-level allergen characterization
• Point-of-Care (POC) allergy kits for rapid screening in outpatient and telehealth settings
• Artificial intelligence-based decision support tools for allergic response prediction

Subscribe for Real-Time Updates on Diagnostic Innovations, FDA Approvals, and M&A Activity @ https://www.delveinsight.com/sample-request/allergy-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Analysts Commentary
The global allergy diagnostics market is positioned for sustained double-digit growth through 2032, supported by rising allergy incidence, technological innovation, and expanded clinical adoption. As healthcare systems worldwide shift toward preventive and precision-based medicine, allergy diagnostics will continue to play a pivotal role in patient safety and treatment personalization.

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.